Your browser doesn't support javascript.
loading
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.
Primo, Daniel; Scarfò, Lydia; Xochelli, Aliki; Mattsson, Mattias; Ranghetti, Pamela; Espinosa, Ana Belén; Robles, Alicia; Gorrochategui, Julian; Martínez-López, Joaquín; de la Serna, Javier; González, Marcos; Gil, Alberto Chaparro; Anguita, Eduardo; Iraheta, Sandra; Munugalavadla, Veerendra; Quéva, Christophe; Tannheimer, Stacey; Rosenquist, Richard; Stamatopoulos, Kostas; Ballesteros, Joan; Ghia, Paolo.
Afiliación
  • Primo D; Vivia Biotech, Tres Cantos, Madrid, Spain.
  • Scarfò L; Strategic Research Program on CLL and B Cell Neoplasia Unit, Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy.
  • Xochelli A; Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.
  • Mattsson M; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Ranghetti P; Strategic Research Program on CLL and B Cell Neoplasia Unit, Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy.
  • Espinosa AB; Vivia Biotech, Tres Cantos, Madrid, Spain.
  • Robles A; Vivia Biotech, Tres Cantos, Madrid, Spain.
  • Gorrochategui J; Vivia Biotech, Tres Cantos, Madrid, Spain.
  • Martínez-López J; Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • de la Serna J; Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • González M; Hematology Service, IBSAL-Hospital Universitario, Centro de Investigación del Cáncer (CIC)- IBMCC, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Universidad de Salamanca, Salamanca, Spain.
  • Gil AC; Department of Hematology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.
  • Anguita E; Department of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain.
  • Iraheta S; Department of Hematology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.
  • Munugalavadla V; Department of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain.
  • Quéva C; Department of Hematology and Hemotherapy, Hospital Universitario de Canarias, La Laguna, Spain.
  • Tannheimer S; Gilead Sciences, Foster City, CA, USA.
  • Rosenquist R; Gilead Sciences, Foster City, CA, USA.
  • Stamatopoulos K; Gilead Sciences, Foster City, CA, USA.
  • Ballesteros J; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Ghia P; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Oncotarget ; 9(40): 26019-26031, 2018 May 25.
Article en En | MEDLINE | ID: mdl-29899839
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: España